Skip to content
Back to Investors
Nina Capital

Nina Capital

Venture Capital

Nina Capital is a European venture capital firm focused on early stage investments in health technology companies.

Portfolio

2

companies

By category

  • BioTech£3.7M
  • FemTech£2.1M

By location

  • Cambridge£3.7M
  • London£2.1M

Portfolio companies

The Lowdown

The Lowdown

A digital health platform providing contraception reviews, expert consultations, and community support for women.

ZG

Zetta Genomics

Zetta Genomics builds genomic data analysis platforms for precision medicine and healthcare.


Team

Marta Gaia Zanchi

Marta Gaia Zanchi

Founder & Managing Partner

Marta is the founding managing partner at Nina Capital. She also serves as a board director for DataJoint, MedaSystems, Cardiomatics, and PlenOptika.

LinkedIn
Marc Subirats

Marc Subirats

General Partner

Marc serves as general partner at Nina Capital and holds board directorships at Zetta Genomics and Methinks AI. He previously operated as general manager of international business at Teladoc Health.

LinkedIn

Recent investments

Seed
£1.8M

The funding extension was backed by new investor We Venture Capital alongside returning backers Nina Capital, Apex Ventures, and Cambridge Enterprise to prepare the firm for Series A.

"Zetta Genomics is already making a difference to patients as XetaBase empowers clinicians to make faster and more accurate diagnoses at scale. With this extension to our second seed funding round now finalised, we are scaling and innovating our technologies, and enhancing customer focus."
— Ignacio Medina, Founder and CEO
Seed
£1.9M

Nina Capital led the seed follow on round to support international growth and product scaling.

"Today’s seed funding exceeded our initial ask, showing the excitement building around Zetta Genomics’ game changing XetaBase data analytics platform. We now have the strategic headroom to configure for growth – to scale our technologies, enhance customer focus, and create a cycle of ongoing product innovation. This investment sees us one step closer to realising predictive, precision genomics – transforming research, healthcare and the lives of millions."
— Mark Bailey, CEO
Seed
£2.1M

The seed round was co-led by Speedinvest and Nina Capital to fund international expansion and team growth.

"The time to invest in Women’s reproductive health is now. Alice’s ability to build community, content, and tools that women love but have never had access to is second- to-none. Contraception is just the start of The Lowdown’s bold vision in Women’s health and we are thrilled to be supporting them on it!"
— Andrea Zitna, Health team lead